Chemomab Therapeutics Ltd Share Price

NASDAQ: CMMB

Small Cap

$3.03

-0.02

(-0.58%)

as on September 13, 2025 at 1:29 am IST

$₹

Chemomab Therapeutics Ltd Stock Performance

as on September 13, 2025 at 1:29 am IST

Day's Low
Day's High
$3.01
Day's Price Range
$3.09
$3.03
0.66%
Downside
1.98%
Upside
52 Week's Low
52 Week's High
$2.96
52-Week Price Range
$9.84
$3.03
2.30%
Downside
224.75%
Upside

Chemomab Therapeutics Ltd share price movements today

Previous Close: $3.05
Open: $3.02
Volume: 221.0K
Day's Low - High: $3.01 - $3.09
52 Week Low - High: $2.96 - $9.84

Chemomab Therapeutics Ltd Historical Returns

1 Month Return: -20.41 %
3 Month Return: -36.46 %
1 Year Return: -57.28 %
3 Year Return: -76.82 %
5 Year Return: -98.82 %

Chemomab Therapeutics Ltd Stock Fundamentals & Key Indicators

Check Chemomab Therapeutics Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$15.8M

EPS (TTM)

-0.08

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

EBITDA

-12.6M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

52369800.00%

Chemomab Therapeutics Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Chemomab Therapeutics Ltd with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Chemomab Therapeutics Ltd	BUY	$15.8M	-98.82%	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	280.5%	-505.15	-12.96%
Beone Medicines Ltd	NA	$37.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.2B	54.04%	28.08	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	2.03%	14.11	31.37%

Stock Returns calculator for Chemomab Therapeutics Ltd Stock including INR - Dollar returns

The Chemomab Therapeutics Ltd stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Chemomab Therapeutics Ltd investment value today

Current value as on today

₹47,576

Returns

₹52,424

(-52.42%)

Returns from Chemomab Therapeutics Ltd Stock

₹57,563 (-57.56%)

Dollar Returns*

₹5,139 (+5.14%)

Analyst Recommendation on Chemomab Therapeutics Ltd Stock

Based on 8 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 8 analysts, 75% of analysts recommend a 'BUY' rating for Chemomab Therapeutics Ltd. Average target price of $29.67

Chemomab Therapeutics Ltd Share Price Target

Get share price movements and forecasts by analysts on Chemomab Therapeutics Ltd.

What analysts predicted

89.79%UPSIDE

Target Price

$29.67

Current Price

$3.03

Analyzed by

8 Analysts

Target

$29.67

Chemomab Therapeutics Ltd target price $29.67, a slight upside of 89.79% compared to current price of $3.03. According to 8 analysts rating.

Chemomab Therapeutics Ltd Stock's Interest Amongst Investors

Search interest for Chemomab Therapeutics Ltd Stock has increased by 44% in the last 30 days, reflecting an upward trend in search activity.

Time period: August 15, 2025 to September 14, 2025

Change:44% versus previous 30 day period

Chemomab Therapeutics Ltd Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-9	0	0	0	-	0	-	-	-	0
Operating Income	-9	-8	-4	-3	-4	-3	-3	-3	-3	-2
EBITDA	-9	-8	-4	-3	-4	-3	-3	-3	-3	-2
Interest Expense	17	-	-	-	0	0	-	-	-	-
Depreciation	0	0	-	-	-	-	-	-	-	-
Income Before Tax	-8	-7	-4	-3	-3	-3	-3	-2	-3	-2
Income Tax Expense	0	0	0	0	0	0	-	-	-	-
Net Income	-8	-7	-4	-3	-3	-3	-3	-2	-3	-2
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Chemomab Therapeutics Ltd Annual Profit & Loss

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0
Operating Income	-9	12	27	-5	-12	-28	-25	-14
EBITDA	-9	12	27	-5	-12	-28	-25	-13
Interest Expense	0	-	4	0	0	0	-	-
Depreciation	0	0	0	0	0	0	0	0
Income Before Tax	-9	12	27	-5	-12	-28	-24	-13
Income Tax Expense	0	0	0	0	0	0	0	-
Net Income	-9	13	27	-5	-12	-27	-24	-13
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Chemomab Therapeutics Ltd Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-7	-4	-3	-3	-3	-3	-2	-3	-2
Operating Cash Flow	-7	-5	-3	-	-	-	-	-	-
Investing Cash Flow	-4	3	1	-	-	-	-	-	-
Financing Cash Flow	1	0	2	-	-	-	-	-	-
Change in Cash	-10	-1	0	-	-	-	-	-	-

Chemomab Therapeutics Ltd Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-4	-9	-13	-27	-5	-12	-27	-24	-13
Operating Cash Flow	-3	-8	-14	-16	-5	-12	-20	-23	-15
Investing Cash Flow	0	0	0	0	0	-45	19	15	2
Financing Cash Flow	6	5	20	26	4	61	0	3	9
Change in Cash	2	-3	6	10	0	3	-1	-4	-3

Global Institutional Holdings in Chemomab Therapeutics Ltd

Funds	Holdings
Advisory Services Network, LLC	0%

Insights on Chemomab Therapeutics Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.7% return, outperforming this stock by 133.5%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 123.7% return, outperforming this stock by 200.6%
NEGATIVE IMPACT
Price Dip
In the last 1 month, CMMB stock has moved down by -16.1%

About Chemomab Therapeutics Ltd

chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).

Organisation	Chemomab Therapeutics Ltd
Headquarters	Building 7, Tel Aviv, Israel, 6158002
Industry	Healthcare
CEO	Dr. Adi Mor George Ph.D.
E-voting on shares	Click here to vote

Key Management of Chemomab Therapeutics Ltd

Name	Title
Dr. Adi Mor George Ph.D.	Co-Founder, Chief Scientific Officer, CEO & Executive Director
Ms. Sigal Fattal CPA, M.B.A.	Chief Financial Officer
Barbara Lindheim	Consulting Vice President of Investor & Public Relations, Strategic Communications
Dr. David M. Weiner M.B.A., M.D.	Interim Chief Medical Officer
Mr. Jack Lawler	Chief Development Officer

FAQs

What is Chemomab Therapeutics Ltd share price today?

Chemomab Therapeutics Ltd share price today is $3.03 as on September 13, 2025 at 1:29 am IST at the close of the market. Chemomab Therapeutics Ltd share today touched a day high of $3.09 and a low of $3.01.

What is the 52 week high and 52 week low for Chemomab Therapeutics Ltd share?

Chemomab Therapeutics Ltd share touched a 52 week high of $9.84 on January 7, 2025 and a 52 week low of $2.96 on September 10, 2025. Chemomab Therapeutics Ltd stock price today i.e. September 13, 2025 at 1:29 am IST is closed at $3.03,which is 69.21% down from its 52 week high and 2.36% up from its 52 week low.

What is Chemomab Therapeutics Ltd's market capitalisation today?

Chemomab Therapeutics Ltd market capitalisation is $0.00T as on September 13, 2025 at 1:29 am IST.

How to invest in Chemomab Therapeutics Ltd Stock (CMMB) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Chemomab Therapeutics Ltd on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Chemomab Therapeutics Ltd Shares that will get you 0.4950 shares as per Chemomab Therapeutics Ltd share price of $3.03 per share as on September 13, 2025 at 1:29 am IST.

What is the minimum amount required to buy Chemomab Therapeutics Ltd Stock (CMMB) from India?

Indian investors can start investing in Chemomab Therapeutics Ltd (CMMB) shares with as little as ₹88.27 or $1 (as of September 14, 2025 at 11:43 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹882.70 in Chemomab Therapeutics Ltd stock (as per the Rupee-Dollar exchange rate as on September 14, 2025 at 11:43 am IST). Based on Chemomab Therapeutics Ltd share’s latest price of $3.03 as on September 13, 2025 at 1:29 am IST, you will get 3.3003 shares of Chemomab Therapeutics Ltd. Learn more about fractional shares .

What are the returns that Chemomab Therapeutics Ltd has given to Indian investors in the last 5 years?

Chemomab Therapeutics Ltd stock has given -98.82% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?